Radiopharm Theranostics Limited American Depositary Shares (RADX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Radiopharm Theranostics Limited American Depositary Shares (RADX) has a cash flow conversion efficiency ratio of -0.446x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.26 Million) by net assets ($49.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RADX equity to assets ratio to measure how much of total assets are equity-financed.
Radiopharm Theranostics Limited American Depositary Shares - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Radiopharm Theranostics Limited American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore long-term investment intensity of Radiopharm Theranostics Limited American to see how much of total assets are deployed in long-term investments.
Radiopharm Theranostics Limited American Depositary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Radiopharm Theranostics Limited American Depositary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ever Shine Textile Industry
JK:ESTI
|
0.027x |
|
Sungmoon Elect
KO:014910
|
0.013x |
|
The Peria Karamalai Tea & Produce Company Limited
NSE:PKTEA
|
-0.002x |
|
Medipharm Labs Corp
TO:LABS
|
-0.022x |
|
Q/C Technologies, Inc.
NASDAQ:QCLS
|
-0.139x |
|
Aurora Mobile Ltd
NASDAQ:JG
|
0.048x |
|
Klaria Pharma Holding AB
ST:KLAR
|
0.004x |
|
Seojin Automotive Co.Ltd
KQ:122690
|
0.107x |
Annual Cash Flow Conversion Efficiency for Radiopharm Theranostics Limited American Depositary Shares (2022–2025)
The table below shows the annual cash flow conversion efficiency of Radiopharm Theranostics Limited American Depositary Shares from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see Radiopharm Theranostics Limited American (RADX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $42.87 Million | $-36.65 Million | -0.855x | -1.76% |
| 2024-06-30 | $27.35 Million | $-22.98 Million | -0.840x | -65.01% |
| 2023-06-30 | $45.58 Million | $-23.20 Million | -0.509x | -223.23% |
| 2022-06-30 | $62.96 Million | $-9.92 Million | -0.157x | -- |
About Radiopharm Theranostics Limited American Depositary Shares
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; R… Read more